Opiate antagonist facilitation of time-dependent memory processes: dependence upon intact norepinephrine function

Significance and Remembrance: The Role of Neuromodulatory Systems

It is now well known that the retention of newly-acquired information can be modulated by drugs or hormones administered shortly following training. It is generally thought that such treatments influence retention by modifying processes underlying the storage of information. The fact that susceptibility to posttraining memory modulation is seen in many species, including bees, fish, birds, and mammals, argues that some common time-dependent memory storage processes have been conserved in evolution. Recent research findings have provided strong support for the view that such susceptibility to posttraining influences provides opportunity for modulation of memory storage by endogenous neurohormonal systems. In rats and mice, posttraining administration of hormones such as epinephrine that are normally released by training experiences enhances subsequent retention. Comparable effects are found with posttraining administration of opiate receptor antagonists such as naloxone. Findings of recent experiments indicate that these treatments affect memory by influencing the release of norepinephrine within the amygdaloid complex. The endogenous regulation of memory storage appears to involve interaction of neurohormones and transmitters in activating brain systems involved in memory storage.

Endogenous Opioids Interfere with Pavlovian Second-Order Fear Conditioning

Second-order classical (Pavlovian) aversive conditioning was used to determine whether endogenous opiates play a role in the acquisition of associative learning. Second-order conditioning avoids confounding drug effects on associative learning with altered responsiveness to unconditioned stimuli (e.g., hyperalgesia). Administration of the prototypical opiate antagonist naloxone (2.0 mg/kg) prior to the second-order training session specifically facilitated associative learning as indicated by greater lick suppression over 3 days of testing. This result suggests that endogenous opiates retard the acquisition of associative learning, which complements previous studies demonstrating an opioid attenuation of memory consolidation.

Orienting and reorienting: the locus coeruleus mediates cognition through arousal

Mood, motivation, attention, and arousal are behavioral states having a profound impact on cognition. Behavioral states are mediated though the peripheral nervous system and neuromodulatory systems in the brainstem. The noradrenergic nucleus locus coeruleus is activated in parallel with the autonomic system in response to biological imperatives. These responses can be spontaneous, to unexpected salient or threatening stimuli, or they can be conditioned responses to awaited behaviorally relevant stimuli. Noradrenaline, released in forebrain structures, will facilitate sensory processing, enhance cognitive flexibility and executive function in the frontal cortex, and promote offline memory consolidation in limbic structures. Central activation of neuromodulatory neurons and peripheral arousal, together, prepare the organism for a reorientation or reset of cortical networks and an adaptive behavioral response.

Alzheimer's disease and age-related memory decline (preclinical)

An unfortunate result of the rapid rise in geriatric populations worldwide is the increasing prevalence of age-related cognitive disorders such as Alzheimer's disease (AD). AD is a devastating neurodegenerative illness that is characterized by a profound impairment of cognitive function, marked physical disability, and an enormous economic burden on the afflicted individual, caregivers, and society in general. The rise in elderly populations is also resulting in an increase in individuals with related (potentially treatable) conditions such as "Mild Cognitive Impairment" (MCI) which is characterized by a less severe (but abnormal) level of cognitive impairment and a high-risk for developing dementia. Even in the absence of a diagnosable disorder of cognition (e.g., AD and MCI), the perception of increased forgetfulness and declining mental function is a clear source of apprehension in the elderly. This is a valid concern given that even a modest impairment of cognitive function is likely to be associated with significant disability in a rapidly evolving, technology-based society. Unfortunately, the currently available therapies designed to improve cognition (i.e., for AD and other forms of dementia) are limited by modest efficacy and adverse side effects, and their effects on cognitive function are not sustained over time. Accordingly, it is incumbent on the scientific community to develop safer and more effective therapies that improve and/or sustain cognitive function in the elderly allowing them to remain mentally active and productive for as long as possible. As diagnostic criteria for memory disorders evolve, the demand for pro-cognitive therapeutic agents is likely to surpass AD and dementia to include MCI and potentially even less severe forms of memory decline. The purpose of this review is to provide an overview of the contemporary therapeutic targets and preclinical pharmacologic approaches (with representative drug examples) designed to enhance memory function.

Influence of nitric oxide on morphine-induced amnesia and interactions with dopaminergic receptor agents

The interactions of dopaminergic receptors and nitric oxide (NO) with morphine-induced memory of passive avoidance have been investigated in mice. Pre-training administration of morphine (1, 3 and 5 mg/kg, s.c.) dose-dependently decreased the learning of a one-trial passive avoidance task. Pre-training administration of L-arginine, a nitric oxide precursor (50, 100 and 200 mg/kg, i.p.), alone did not affect memory formation. The drug (100 and 200 mg/kg) decreased significantly amnesia induced by pre-training morphine (5 mg/kg). Pre-training administration of L-NAME (N(G)-nitro-L-arginine methyl ester), a nitric oxide synthase (NOS) inhibitor (20 and 30 mg/kg, i.p.), dose-dependently impaired memory formation. In addition, co-pretreatment of different doses of L-NAME (10, 20 and 30 mg/kg) with lower dose of morphine (1 mg/kg), which did not induce amnesia by itself, caused inhibition of memory formation. Pre-training administration of apomorphine, a dopaminergic receptor agonist (0.25, 0.5 and 1 mg/kg, i.p.), alone also did not affect memory formation, but morphine-induced amnesia was significantly inhibited by pretreatment with apomorphine (0.5 and 1 mg/kg, 5 min, i.p.). On the other hand, the inhibition of morphine-induced amnesia by L-arginine (200 mg/kg, i.p.) was significantly decreased by pretreatment with different doses of dopamine D1 receptor antagonist, SCH 23390 (0.001, 0.01 and 0.1 mg/kg, i.p.) or D2 receptor antagonist, sulpiride (12.5, 25, 50 and 100 mg/kg, i.p.). However, the dopamine receptor antagonists could not affect memory formation by themselves. It may be concluded that the morphine-induced impairment of memory formation can be prevented by nitric oxide donor and, in this effect, dopaminergic mechanism is involved.

Role of the basolateral amygdala in memory consolidation

Memories of emotionally arousing events tend to be more vivid and to persist longer than do memories of neutral or trivial events. Moreover, memories of emotionally influenced information may endure after a single experience. Recent findings strongly suggest that the influence of emotional arousal on memory consolidation is mediated by the release of adrenal stress hormones (epinephrine and glucocorticoids) and neurotransmitters that converge in modulating the noradrenergic system within the amygdala. Considerable evidence also indicates that amygdala activation influences memory by regulating consolidation in other brain regions. The findings suggest further that this memory-modulatory system may be involved in the formation of traumatic memories and posttraumatic stress disorder in human subjects.

Role of adrenoceptor subtypes in memory consolidation

Noradrenaline release in areas within the forebrain occurs following activation of noradrenergic cells in the locus coeruleus (LoC). Release of noradrenaline by attentional/arousal/vigilance factors appears to be essential for learning and is responsible for the consolidation of memory. Noradrenaline can activate any of nine different adrenoceptor (AR) subtypes in the brain and selectivity of action may be achieved by the spatial location and relative density of the AR subtypes, by different affinities of the different subtypes and by temporal selectivity in terms of when the different ARs are activated in the memory formation process. This review examines the use of selective agonists and antagonists to determine the roles of the AR subtypes in the one-trial discriminated avoidance learning paradigm in the chick. A model is developed that integrates noradrenergic activity in basal ganglia (lobus parolfactorius (LPO)) and association cortex (intermediate medial hyperstriatum ventrale (IMHV)) leading to the consolidation of memory 30 min after training. There is evidence that beta(2)- and beta(3)-ARs are important in the association area but require input from alpha(2)-AR stimulated activity in the basal ganglia for consolidation. On the other hand, alpha(1)-AR activation in the IMHV is inhibitory and prevents consolidation. While there is no role for beta(1)-ARs in memory consolidation, they play a role in short-term memory (STM). The use of the precocial chick has clear advantages in having a temporally discrete learning task which allows for discrimination memory and whose development can be followed at discrete intervals after learning. These studies reveal clear roles for AR subtypes in the formation and consolidation of memory in the chick, which have allowed the development of a model that can now be tested in mammalian systems.

"Silent" metaplasticity of the late phase of long-term potentiation requires protein phosphatases

The late phase of long-term potentiation (L-LTP) is correlated with some types of long-term memory, but the mechanisms by which L-LTP is modulated by prior synaptic activity are undefined. Activation of protein phosphatases by low-frequency stimulation (LFS) given before induction of L-LTP may significantly modify L-LTP. Using cellular electrophysiological recording methods in mouse hippocampal slices, we show that LFS given before induction of L-LTP inhibited L-LTP in an activity-dependent manner without affecting either basal synaptic strength or the early phase of LTP (E-LTP). This anterograde inhibitory effect of LFS was persistent, required N-methyl-D-aspartate (NMDA) receptor activation, and was blocked by inhibitors of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A). These data indicate that certain patterns of LFS can activate PP1 and/or PP2A, and that long-lasting activation of these phosphatases by prior LFS can suppress the subsequent expression of L-LTP without affecting E-LTP. Because this inhibition of L-LTP is caused by prior synaptic activity that, alone, produced no net effect on synaptic efficacy, we suggest that this is a "silent" form of metaplasticity that may influence long-term information storage by modulating the capacity of synapses to express L-LTP after repeated bouts of activity.

Peripheral modulation of learning and memory: enkephalins as a model system

Extensive research on the effects of enkephalins on conditioning is reviewed and used as the basis for a model of peripheral modulation of learning and memory. An overall theme emphasized throughout our discussion is that these peptides can influence the strength with which a memory is acquired and stored by acting outside the blood-brain barrier. This assertion is supported by research on the behavioral effects of systemically administered enkephalins and opioid antagonists, the rapid hydrolysis of circulating enkephalins in vivo, and the limited ability of these peptides to penetrate the blood-brain barrier. A consideration of the extensive distribution of enkephalins throughout peripheral autonomic systems leads to the proposal that enkephalins may act to modulate learning and memory by altering peripheral autonomic function; autonomic afferents may then communicate with the memory trace in the CNS through a central modulatory pathway outlined herein. Evidence that some stressful experiences may lead to increases in circulating enkephalins also is discussed. The sites of action of these circulating enkephalins may involve peripheral autonomic sites, or additionally may involve the circumventricular organs. As a further regulatory mechanism, circulating enkephalin levels may be controlled by experience-dependent alterations of the activity of enzyme systems that participate in their breakdown. Finally, it is emphasized that the mechanisms of enkephalin action postulated herein may be applicable to the actions of other peripheral hormones, peptides, and neurotransmitters that participate in the modulation of learning and memory storage processes.

Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala

There is extensive evidence indicating that the noradrenergic system of the amygdala, particularly the basolateral nucleus of the amygdala (BLA), is involved in memory consolidation. Infusions of norepinephrine or beta-adrenoceptor agonists into the BLA enhance memory for inhibitory avoidance as well as water maze training. Other findings show that alpha 1-adrenoceptor activation also enhances memory for inhibitory avoidance training through an interaction with beta-adrenergic mechanisms. The central hypothesis guiding the research reviewed in this chapter is that stress hormones released during emotionally arousing experiences activate noradrenergic mechanisms in the BLA, resulting in enhanced memory for those events. Findings from experiments using rats have shown that the memory-modulatory effects of the adrenocortical stress hormones epinephrine and glucocorticoids are mediated by influences involving activation of beta-adrenoceptors in the BLA. In addition, both behavioral and microdialysis studies have shown that the noradrenergic system of the BLA also mediates the influences of other neuromodulatory systems such as opioid peptidergic and GABAergic systems on memory storage. Other findings indicate that this stress hormone-induced activation of noradrenergic mechanisms in the BLA regulates explicit/declarative memory storage in other brain regions.

Dopamine and opioid regulation of the memory retrieval recovery in mice

The reactivation effects of the delta-opioid receptor blockade and D2 dopamine receptor activation on the detention-induced memory deficit in mice were investigated, in order to study possible interactions between opioid and dopamine systems in memory retrieval. Animals were trained in a one-trial passive-avoidance task. Pretesting treatment with ICI 174,864 (1, 3 or 5 mg/kg, i.p.) or quinpirole (0.5, 1 or 2 mg/kg, i.p.) facilitated retrieval of memory trace in saline-pretreated mice. Pretraining injection of the dopamine autoreceptor agonist, (+)-3PPP (2 mg/kg), having no effect alone in learning, prevented the ability of ICI 174,864 to produce the memory-enhancing effect. It is suggested that the normal functioning of the dopamine system was critical for the facilitation of retrieval by delta-antagonist. Quinpirole-induced reactivátion of memory retrieval was enhanced by pretreatment with Leu-enkephalin (0.2 mg/kg), inducing increased retention. We discuss these results in the context of an important interactions between D2 dopamine and delta-opioid receptors.

Psychopharmacology of memory modulation: evidence for multiple interaction among neurotransmitters and hormones

Experimental results are reviewed which indicate that memory storage can be altered by a number of post-training treatments that affect different hormones and neurotransmitters. Moreover, evidence was reported which suggests that the action of treatments effective on memory processes involves interactions among different systems, consistently with the complexity of brain systems. In the last decade, inbred strains have been exploited to investigate the role of neurotransmitter and hormone systems in learning and memory, leading to behavioural and neurochemical correlations based on strain differences that provide unique information on the biological systems underlying behaviour. Research carried out on the inbred strains of mice C57BL/6 (C57) and DBA/2 (DBA), demonstrates that the genetic makeup plays an important role in modulating response to drug administration. Thus, recent results have shown that in C57 mice, similarly to what occurs in outbred strains of mice or in rats, GABAergic agonists impair memory and antagonists improve it, whilst the opposite is evident in the DBA strain. By contrast, post-training administration of selective D1 or D2 agonists impairs and post-training administration of selective antagonists improves retention in DBA mice, whilst these agents have opposite effects in the C57 strain. Dose- and strain-dependent effects are evident also following post-training corticosterone as well as opioid agonists and antagonists administration. On the other side, these two strains react similarly to oxotremorine (improvement) and to atropine (impairment) administration, DBA mice being more responsive to the effects of both drugs than C57 mice. Data on the interactions between agents acting upon different neurotransmitter and/or hormonal systems in these strains indicate strain-dependent synergistic or antagonistic interactions among some of these systems, pointing to inbred strains of mice as an important methodological tool in the study of neural and hormonal factors involved in emotion and in its effects on cognition. In particular, these studies have been carried out on inbred strains of mice from which recombinant inbred (RI) strains are available that have recently been proposed as a choice experimental method in psychopharmacogenetics.

Neuromodulatory systems and memory storage: role of the amygdala

This article reviews findings of research examining the interaction of peripheral adrenergic systems with cholinergic, opioid peptidergic and GABAergic systems in modulating memory storage. It is well established that retention is enhanced by posttraining systemic or intra-amygdala injections of adrenergic agonists, opiate antagonists and GABAergic antagonists. These influences appear to be mediated by activation of NE receptors within the amygdala, as intra-amygdala injections of beta-adrenergic antagonists block the memory-modulating effects of hormones and drugs affecting these systems. Furthermore, these influences also appear to involve, at a subsequent step, activation of a cholinergic system: atropine blocks the memory-enhancing effects of adrenergic agonists and opiate and GABAergic antagonists and oxotremorine attenuate the memory-impairing effects of opiate agonists and GABAergic agonists. These findings suggest that the amygdala integrates the memory-modulating effects of neuromodulatory systems activated by learning experiences.

Hippocampal CRF, NE, and NMDA system interactions in memory processing in the rat

In the present study, we investigated the neural mechanisms of corticotropin-releasing factor (CRF) and the interactions among CRF, norepinephrine (NE), and N-methyl-D-aspartate (NMDA) systems in the dentate gyrus (DG) of hippocampus in modulating the memory process of rats. One-way passive avoidance task was adopted. Results indicated that CRF (80 ng), when directly injected into the DG, consistently and significantly enhanced memory retention in rats. The noradrenergic neurotoxin DSP-4, at a high dose (4 micrograms), impaired memory. DSP-4 at a moderate dose (2 micrograms), which did not affect retention alone, antagonized the memory-enhancing effect of CRF. Similarly, the beta-adrenergic antagonist propranolol, at a high dose (8 micrograms), reduced retention. At a low dose (80 ng), which did not markedly affect retention by itself, propranolol also prevented the memory-improving effect of CRF. Moreover, direct NE infusions to the DG significantly improved retention performance in a dose-sensitive manner. Coadministration of CRF and NE did not further enhance retention. These results together suggest that CRF and NE facilitated memory probably through the same instead of independent mechanisms. In contrast, the selective NMDA receptor antagonists 2-amino-5-phosphonopentanoate (AP5) and MK801, at high doses markedly impaired memory retention (0.8 and 3.2 micrograms for AP5, 2 and 10 micrograms for MK801). At a dose of MK801 that did not significantly alter retention alone (80 ng), it completely blocked the memory-facilitating effect of CRF. These results indicate that CRF enhanced memory indirectly through NMDA receptor mediation also. Finally, MK801 at 80 ng also successfully antagonized the memory-facilitating effect of NE in the DG. We have demonstrated that MK801, at the dose chosen for interaction studies, did not markedly alter locomotor activity. These results together suggest that CRF, through a presynaptic facilitation mechanism, possibly facilitates NE release in the DG; increased NE release and stimulation of beta-adrenergic receptors in the DG result in NMDA receptor activations in the same area. This sequence of events enhance the memory consolidation process in the hippocampus and explained the neural mechanism of CRF in facilitating retention performance in rats. The same neuropeptide/neurotransmitter interactions may have other physiological and neuropathological implications.

Noradrenergic involvement in the consolidation of maternal experience in postpartum rats

If postpartum rats are separated from pups following cesarean delivery, their maternal responsiveness declines such that in tests on day 10 they show maternal onset latencies that do not differ from those shown by virgin rats. If, however, dams are permitted a 1-h experience with pups within 36 h of cesarean delivery, rats exhibit a high level of responsiveness to foster pups on day 10 after c-section. The present research investigates the effect of the noradrenergic system in the long-term consolidation of a brief maternal experience in new mother rats. Groups of dams were cesarean delivered and were either given pups for a brief period 36 h after section (experienced) or received no experience (inexperienced). Immediately following the experience phase, dams were injected with different concentrations of the beta-adrenergic antagonist, propranolol (0, 0.5, 1.0, 5.0 mg/kg), or the adrenergic agonist, isoproterenol (0, 0.25 or 0.5 mg/kg). Ten days after cesarean delivery rats were given maternal induction tests. Rats receiving 60 min of experience and injected with propranolol exhibited significantly longer maternal onset latencies than did saline-injected rats, although their latencies were not as long as shown by the maternally inexperienced groups. In contrast, rats receiving 15 min of experience and injected with isoproterenol exhibited significantly shorter onset latencies than did saline-injected rats, whether or not they exhibited maternal behavior during the initial 15 min exposure period. These results suggest that the noradrenergic system is involved in the consolidation of a maternal experience.

Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala

Mice, partially trained to avoid footshock in a T-maze, showed enhanced retention relative to vehicle-injected mice when treated peripherally with arecoline, D-amphetamine, cholecystokinin octapeptide (CCK-8), epinephrine or naloxone. Both intra-amygdaloid and intraventricular injections of beta-endorphin resulted in amnesia. D-amphetamine and arecoline blocked the amnestic effect of beta-endorphin administered into the amygdala but it required higher doses for CCK-8, epinephrine and naloxone to block the amnestic effect of beta-endorphin. The effects of CCK-8, epinephrine and naloxone showed a differential ability to block amnesia induced by beta-endorphin intraventricularly with epinephrine and naloxone preventing amnesia but CCK-8 not improving retention. This data suggests that the memory enhancement produced by peripherally administered CCK-8 involves the amygdala and that both CCK-8 and epinephrine interact with opioid amnestic mechanisms within the amygdala to alter memory processing.

Involvement of the amygdala in the memory-enhancing effects of clenbuterol

Male Sprague Dawley rats with stria terminalis (ST) or sham lesions were trained in an inhibitory avoidance task, injected immediately post-training with clenbuterol hydrochloride (0.03 mg/kg; IP), and tested for retention 48 h later. Clenbuterol enhanced retention of the sham-lesioned animals but did not affect retention of the ST-lesioned animals. Clenbuterol injected intraamygdally immediately after training also enhanced retention of the inhibitory avoidance task. These results agree with other evidence suggesting the participation of beta-noradrenergic mechanisms in the amygdala in the modulation of memory storage.

Involvement of the amygdaloid complex in neuromodulatory influences on memory storage

Neuromodulatory systems activated by training experiences appear to play a role in influencing memory storage processes. The research summarized in this paper examined the effects, on memory, of posttraining administration of treatments affecting adrenergic, opioid peptidergic and GABAergic systems. When administered after training, drugs affecting these systems all produce dose- and time-dependent effects on memory storage. The drug effects on memory are blocked by lesions of the amygdaloid complex as well as lesions of the stria terminalis, a major amygdala pathway. The effects of drugs affecting these neuromodulatory systems are also blocked by injections of beta-adrenergic antagonists administered to the amygdaloid complex. Thus, the findings suggest that the neuromodulatory systems affect memory storage through influences involving the activation of beta-adrenergic receptors within the amygdala. These findings are consistent with the view that the amygdala is involved in regulating the storage of memory in other brain regions.

Opiate antagonists enhance the working memory of rats in the radial maze

Two experiments tested the influence of the opiate antagonists naloxone and naltrexone on the spatial working memory of rats in a 12-arm radial maze. In Experiment 1, ten rats were serially forced to visit six randomly selected arms, then were removed from the maze for delays of either 30, 60, or 240 minutes, and then returned to the maze for a free-choice memory test with all 12 arms available. Five minutes into the delay, rats were injected intraperitoneally (IP) with either physiological saline or naloxone (1 mg/kg). When injected with naloxone the rats revisited forced-choice arms less often than when injected with saline during a subsequent free-choice test. In Experiment 2, twelve rats showed a similar facilitation of working memory when injected with the opiate antagonists naltrexone (0.3 mg/kg) and naloxone (1 mg/kg) in comparison to a saline control condition. These findings demonstrate the beneficial effects that opiate antagonists exert on working memory-based performance in the radial maze. They may also resolve conflicting reports about the influence of opiate antagonists on radial maze performance, by suggesting that the choice of measurement and testing conditions are crucial for detecting these effects in working memory procedures.

Interaction between catecholaminergic and opioid systems in an active avoidance task

Male NMRI mice were given intravenous injections of the noradrenergic neurotoxin DSP4 or the vehicle 24 to 72 h prior behavioral testing. Animals were given 2 days of training on a one-way active avoidance task. Naloxone was given in one of three doses prior to training on Day 1 and Day 2 or prior to training on Day 1 only (saline was given prior to training on Day 2). There was a dose-dependent impairment of acquisition by naloxone in the vehicle-pretreated groups; 10 mg/kg naloxone produced a significant impairment of acquisition. Naloxone also modulated retention (Day 2) performance of the active avoidance task. For vehicle-pretreated mice, 1 mg/kg naloxone facilitated and 10 mg/kg naloxone-impaired performance on Day 2. DSP4 alone produced an impairment of acquisition of this task but had no effect on retention; Day 2 scores were slightly higher in the DSP4-pretreated group than in the vehicle-pretreated group. Naloxone produced somewhat different effects in DSP4-pretreated animals than in vehicle-pretreated animals. Naloxone (1 mg/kg) ameliorated the DSP4-induced impairment of acquisition; 10 mg/kg naloxone did not significantly alter the acquisition performance of this group. For the DSP4-pretreated mice that received naloxone before training on both days, the dose-response characteristics for retention scores were similar to those of vehicle-pretreated mice; 1 mg/kg naloxone was the facilitatory dose. However, for DSP4-treated mice that received naloxone before training on Day 1 only, there was a shift to the right in the effective facilitatory dose of naloxone. For these animals, 10 mg/kg naloxone but not 1 mg/kg naloxone significantly enhanced retention performance. We discuss these results in the context of a possible state-dependent modulation by naloxone in the DSP4-treated animals.

Long-term synaptic potentiation in the amygdala

The manner in which the circuitry of the amygdala computes its suspected mnemonic functions has been a mystery, partly because the cytoarchitectual complexity of this nuclear group has impeded the necessary cellular analysis. Here we report in vitro methods and results that may help elucidate cellular learning mechanisms in amygdala neurons. The amygdala brain slice preparation was combined with the single-electrode clamp (SEC) technique for intracellular analysis of membrane properties and synaptic responses. With respect to the active and passive membrane properties, we found considerable diversity among the population of cells that were sampled in the lateral and basolateral nuclei (n = 85). Synaptic inputs to these neurons were studied by stimulating the external capsule (EC), which was shown to produce a complex response that typically consisted of an excitatory followed by an inhibitory component. Based on several criteria, the excitatory component appeared to reflect a monosynaptic connection from the EC. One immediate goal was to discover whether the excitatory component displays the phenomenon of long-term potentiation (LTP)--a persistent increase in synaptic strength that can be induced by brief periods of the appropriate synaptic stimulation. Indeed, we found that high-frequency (100 Hz) stimulation of the EC induced LTP in 80% of the cells from which suitable recordings were obtained (n = 20). This finding of LTP in the amygdala is significant in regard to current efforts to explore linkages between this use-dependent form of synaptic plasticity and rapid kinds of associative learning.

Modulation of memory processing by neuropeptide Y varies with brain injection site

Neuropeptide Y (NPY) is a 36 amino acid peptide which was shown to enhance memory retention, recall and prevent amnesia induced by either scopolamine or anisomycin. In this study, we examined the effects of NPY administration into 6 areas of the mouse brain on memory retention for footshock avoidance training in a T-maze. NPY was injected into the rostral and caudal hippocampus, amygdala, caudate, septum and thalamus shortly after training. NPY improved retention when injected into the rostral portion of the hippocampus and septum, impaired retention in the caudal portion of the hippocampus and amygdala and had no effect in the thalamus and caudate. NPY was ineffective at either improving or impairing retention when injected 24 h after training, thus demonstrating that the effects of NPY on retention were time-dependent and not due to proactive effects on retention test performance per se. In addition, NPY had no effect on retention when injected into overlying cortical areas. NPY antibody impaired retention when administered into the rostral hippocampus and septum; it improved retention in the caudal hippocampus and amygdala. Thus NPY antibody had the opposite effect to that of NPY on memory retention suggesting that NPY has a physiological role as a modulator of memory processing within specific anatomical areas of the central nervous system.

Idazoxan, an alpha-2 antagonist, facilitates memory retrieval in the rat

The role of the noradrenergic system in cognitive function was studied by using the alpha-2 adrenoceptor antagonist idazoxan to increase noradrenergic activity. Rats were trained in a complex maze task for food reward. They were left undisturbed for a 4-week "forgetting" period and were treated with idazoxan, just before the retention test. The dose of idazoxan used had previously been shown to enhance firing of units of the locus coeruleus and to increase noradrenaline (NE) turnover in the forebrain. This pharmacological treatment effectively alleviated forgetting, while control rats showed significant decrement compared to their performance at the last training trial. A control experiment showed that the facilitative effect was not on learning or on ongoing performance of the task, since there was no effect on simple acquisition. The results are taken as support for the notion that NE plays a role in memory retrieval processes.

Effects of naloxone and naltrexone on memory consolidation in CD1 mice: involvement of GABAergic mechanisms

The involvement of GABAergic mechanisms in the effects exerted by the opioid antagonists naloxone and naltrexone on memory consolidation was investigated in CD1 mice tested in a one-trial inhibitory avoidance task. In a first group of experiments posttraining administration of naloxone (2.0 and 4.0 but not 1.0 mg/kg) and naltrexone (0.5 and 1.0 but not 0.25 mg/kg), as well as those of the GABA-antagonists picrotoxin (0.5 and 1.0 but not 0.25 mg/kg) and bicuculline (0.25 and 0.5 but not 0.1 mg/kg) enhanced, whereas those of the GABA-agonist muscimol (1.0 and 2.0 but not 0.5 mg/kg) impaired retention on a 24-hr test. In a second group of experiments, picrotoxin, or bicuculline, administration enhanced, while muscimol treatment attenuated the effects of naloxone and naltrexone on retention. The results suggest that naloxone and naltrexone may influence memory consolidation in CD1 mice by interacting with the GABAergic system.

Effects of concurrent manipulations of cholinergic and noradrenergic function on learning and retention in mice

Interactions between the neuromodulators acetylcholine and norepinephrine (NE) have been reported in both developmental neural plasticity and learning and memory. In a test of the generality of this phenomenon, we assessed the amnestic effects of the muscarinic antagonist scopolamine in normal and NE-depleted mice. Pretraining administration of scopolamine impaired 24-h retention of inhibitory (passive) avoidance training (at doses of 0.1, 0.3 and 1.0 mg/kg) and the acquisition of place-training in a water maze (at a dose of 1.0 mg/kg). NE depletion resulting from systemic administration of DSP-4 did not affect performance on these tasks and did not significantly alter the effects of scopolamine. NE depletion did, however, impair the retention of place learning when mice were retested 16 days after initial training; and this impairment in the retest was additive with one observed in mice originally trained under scopolamine. Normal acquisition but rapid forgetting has also been reported in aged rodents, who display deterioration of the noradrenergic system. Thus, observation of a similar pattern of performance consequent to experimental NE depletion suggests a role for noradrenergic dysfunction in age-related memory decline.

Memory-enhancing effects of posttraining naloxone: involvement of beta-noradrenergic influences in the amygdaloid complex

Rats (220-250 g) were bilaterally implanted with cannulae in the amygdala, trained on an inhibitory avoidance response and two weeks later, on a Y-maze discrimination response. Immediately following the training on each task, they were injected intraperitoneally (i.p.) or intra-amygdally. Retention was tested one week after training for each task. Retention of the Y-maze task was assessed by discrimination reversal training. Naloxone administered i.p. (3.0 mg/kg) significantly facilitated retention of both tasks in unoperated control rats as well as in rats implanted bilaterally with amygdala cannulae. The memory-enhancing effect of naloxone i.p. was blocked by propranolol (0.3 or 1.0 microgram) injected in the amygdala, but not when this beta-noradrenergic antagonist was injected (0.3 micrograms) into either the caudate or the cortex dorsal to the amygdala. Further, intra-amygdala injections of the beta 1-adrenoceptor blocker atenolol (0.3 or 1.0 microgram) and the beta 2-adrenoceptor blocker zinterol (0.3 or 1.0 microgram), in doses which were ineffective when administered alone, blocked naloxone-induced (3.0 mg/kg, i.p.) memory facilitation. In contrast, posttraining intra-amygdala administration (1.0 micrograms) of the alpha-antagonists prazosin (alpha 1) or yohimbine (alpha 2) did not attenuate the memory-enhancing effects of systemically administered naloxone. These findings support the view that naloxone-induced enhancement of memory is mediated by the activation of beta- but not alpha-noradrenergic receptors located within the amygdaloid complex.

Antagonism of endogenous opioids modulates memory processing

The studies reported here demonstrate that opioid antagonism enhances memory in two classes of animals viz. Aves and Mammalia. In mice, immediate posttraining administration of naloxone produces a time-dependent improvement in retention tested one week later. This effect is stereospecific. As naloxone was approximately 1000-fold more potent when administered intracerebroventricularly compared to subcutaneously, it appears that it produces its effect within the central nervous system. Pretest administration of naloxone, at a dose that failed to alter acquisition, also improved test performance, suggesting that naloxone also improved recall. Similar improvement in retention was demonstrated with the more potent opioid antagonist, nalmefene, at a 500-fold lower dose. The dose response to naloxone in both the mouse and the chick and to nalmefene in the mouse had the characteristics of an inverted U, with high doses either being ineffective or suppressing memory retention. In mice, naloxone demonstrated anti-amnestic properties against both anisomycin, a protein synthesis inhibitor, and scopolamine, an acetylcholine receptor blocker. Administration of beta-funaltrexamine (B-FNA) 72 h prior to training did not alter acquisition but did enhance retention. In studies where the mu-opioid receptor was blocked with B-FNA, naloxone was unable to enhance retention. B-FNA failed to impair the memory enhancing properties of arecoline, fluoxetine or clonidine. This demonstrates specificity of the B-FNA ability to prevent naloxone from enhancing memory and suggests that the opioid antagonist effects on memory are mediated by the mu-receptor.

Modulation of memory processing by neuropeptide Y

Neuropeptide Y (NPY) is a 36 amino acid peptide which occurs in high concentrations in the amygdala and the hippocampus. The studies reported here demonstrate that administration of porcine NPY into the third ventricle of the brain enhanced memory retention for T-maze footshock avoidance and step-down passive avoidance training in mice. Human NPY at 5 micrograms enhanced retention but the inactive free acid form for NPY did not. NPY at 5 micrograms administered subcutaneously did not enhance retention. Post-training administration of NPY produced a dose-dependent, inverted U-shaped dose-response curve for retention of both passive and active avoidance conditioning. NPY enhanced retention in a time-dependent manner. NPY was also found to alleviate the amnesia caused by anisomycin, a protein synthesis inhibitor, and scopolamine, an anticholinergic. Pre-test administration of NPY improved recall but did not affect acquisition. These data support the concept that NPY is a modulator of memory processes.

Endogenous opiates: 1985

This paper is the eighth installment of our annual review of research involving the endogenous opiate peptides. It is restricted to the non-analgesic and behavioral studies of the opiate peptides published in 1985. The specific topics this year include stress, tolerance and dependence, eating, drinking and alcohol consumption, gastrointestinal and renal activity, mental illness, learning and memory, cardiovascular responses, respiration and thermoregulation, seizures and neurological disorders, activity, and some other selected topics.